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ORIGINAL ARTICLE
BET inhibition as a single or combined therapeutic approach in
primary paediatric B-precursor acute lymphoblastic leukaemia
D Da Costa1,4, A Agathanggelou1,4, T Perry1, V Weston1, E Petermann1, A Zlatanou1, C Oldreive1, W Wei1, G Stewart1, J Longman1,
E Smith1, P Kearns1,3, S Knapp2 and T Stankovic1
Paediatric B-precursor ALL is a highly curable disease, however, treatment resistance in some patients and the long-term toxic
effects of current therapies pose the need for more targeted therapeutic approaches. We addressed the cytotoxic effect of JQ1,
a highly selective inhibitor against the transcriptional regulators, bromodomain and extra-terminal (BET) family of proteins, in
paediatric ALL. We showed a potent in vitro cytotoxic response of a panel of primary ALL to JQ1, independent of their prognostic
features but dependent on high MYC expression and coupled with transcriptional downregulation of multiple pro-survival
pathways. In agreement with earlier studies, JQ1 induced cell cycle arrest. Here we show that BET inhibition also reduced c-Myc
protein stability and suppressed progression of DNA replication forks in ALL cells. Consistent with c-Myc depletion and
downregulation of pro-survival pathways JQ1 sensitised primary ALL samples to the classic ALL therapeutic agent dexamethasone.
Finally, we demonstrated that JQ1 reduces ALL growth in ALL xenograft models, both as a single agent and in combination with
dexamethasone. We conclude that targeting BET proteins should be considered as a new therapeutic strategy for the treatment of
paediatric ALL and particularly those cases that exhibit suboptimal responses to standard treatment.
Blood Cancer Journal (2013) 3, e126; doi:10.1038/bcj.2013.24; published online 19 July 2013
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INTRODUCTION
Over the last few decades, a signiﬁcant improvement in the
treatment of children with paediatric B precursor acute lympho-
blastic leukaemia (B-precursor ALL) has been achieved, mostly due
to the rational use of intensive chemotherapy, and careful clinical
and molecular stratiﬁcation.1–3 Despite this, a proportion of
patients still experience disease progression, suggesting a
heterogeneous disease pathogenesis. In addition, a number of
patients suffer from debilitating long-term post-chemotherapy
effects,4,5 and consequently, there is an obvious requirement for
more targeted therapeutic approaches.
The mechanisms underlying chemoresistance and disease
progression in paediatric ALL are still poorly understood. Published
data suggest that in a proportion of patients, progressive disease is
associated with the presence of bcr/abl fusion transcripts, IKZF1
mutations and deletions, activating JAK mutations, or alterations
involving cytokine receptor-like factor 2.6–12 In our previous studies,
we have reported an association between apoptotic resistance to
ionising radiation (IR)-induced DNA damage in vitro and clinical
response in vivo measured by minimal residual disease (MRD).13,14
Furthermore, we observed a connection between apoptotic
resistance and transcriptional deregulation of multiple pro-survival
pathways occurring in a leukaemia-speciﬁc manner. Finally, we
noticed that pharmacological inhibition of individual pro-survival
pathways led to heterogeneous responses in vitro and, therefore,
does not provide a uniform strategy for counteracting apoptotic
resistance.13
With this in mind, we focused on a therapeutic approach that
has the potential to induce cellular death in a range of ALLs with
different phenotypes. The bromodomain and extra-terminal (BET)
family of proteins recently emerged as a new therapeutic target in
haemopoietic malignancies. This family includes four proteins
(BRD2, BRD3, BRD4 and BRDT) that recognise epigenetic
chromatin modiﬁcations, such as polyacetylated lysine residues
of histone tails, and form part of transcription complexes. BRD4
remains bound to transcriptional start sites of genes expressed
during mitosis and affects the transcription of growth- and
survival-promoting genes.15 Interestingly, a recent screen of an
short hairpin RNA library targeting known epigenetic modiﬁers
has identiﬁed BRD4 as the main factor that supports the
maintenance of acute myeloid leukaemia (AML) stem cells.16
A pharmacological inhibitor, JQ1, with high target potency
against BET proteins has recently been synthesised.17 This
inhibitor has demonstrated striking anti-tumour activity in vitro
and in pre-clinical murine models of c-Myc dependent
malignancies such as aggressive nuclear protein in testis-midline
carcinoma, AML and multiple myeloma.17–19 Furthermore, similar
effects were observed in AML cells harbouring MLL fusion genes
treated with another inhibitor against BET proteins, I-BET151.20 It
has been proposed that the main mechanism of JQ1-induced
cytotoxicity involves downregulation of c-Myc as well as Bcl-2; a
principal anti-apoptotic protein.16–19 A more recent study
demonstrated JQ1-induced cytotoxicity in ALL cell lines via
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inhibition of the interleukin-7 (IL-7) receptor and JAK/STAT
signalling pathways.21
Taken together, it seems plausible that BET inhibition induces
multiple cellular effects and that the cytotoxic mechanism in
different haemopoietic malignancies depends on their distinctive
molecular phenotypes. Although a recent report suggests that ALL
might be another haemopoietic malignancy where BET inhibition
is therapeutically beneﬁcial,21 a comprehensive study on primary
ALLs with different features has not been performed. Therefore, the
purpose of this study was to address sensitivity to BET inhibition in
a wide range of primary paediatric ALL samples and expand current
understanding of its cellular effects and the mechanistic aspects of
BET inhibition, with a view of optimising the future therapeutic
application of this promising therapeutic strategy.
We analysed the sensitivity of 26 paediatric primary B-precursor
ALL samples with different clinical and molecular features to JQ1
in vitro and observed a cytotoxic effect irrespective of their
phenotype. Similarly, we noted a complete suppression of ALL
tumour growth in two different xenograft models in NOG mice. In
primary ALL cells, global gene expression proﬁling revealed JQ1-
induced downregulation of multiple pro-survival pathways and a
therapeutic response dependent on the basal expression of cell
cycle regulators c-Myc and its target p21. JQ1 induced cell cycle
arrest and apoptosis, as well as increased replication fork stalling.
Consistent with these ﬁndings, co-treatment of JQ1 with
dexamethasone further suppressed leukaemic cells both in vitro
and in vivo in xenografts created from both a primary ALL and a
dexamethasone-resistant ALL cell line.
MATERIALS AND METHODS
Cell lines and patient samples
We analysed the B-precursor ALL cell lines NALM-6, NALM-17, REH,
SUPB-15, TOM-1, SD1, the T-ALL Jurkat and bone marrow samples from 26
children with B-precursor ALL and two paediatric AML (Supplementary
Table 1). Diagnosis of primary B-precursor ALL or AML was established by
standard morphological and immunophenotypic evaluation. Written
consent was obtained from all patients and control individuals.
Cell viability assays
Viability was assessed using the CellTiter-Glo Luminescent Cell Viability
Assay (Promega, Southampton, UK), according to the manufacturer’s
instructions.
Protein expression analysis
Western blotting was carried out as previously described14 with primary
antibodies: rabbit anti-PARP1 and mouse anti-procaspase-7 (Cell Signaling,
Boston, MA, USA), mouse anti-c-Myc (Calbiochem, San Diego, CA, USA),
rabbit anti-BRD4, anti-BIRC5 and mouse anti-Bcl-2 (Santa Cruz Bio-
technology, Santa Cruz, CA, USA), mouse anti-p53 (DO1) (Roger Grand,
University of Birmingham, UK), rabbit anti-phospho-p53 Ser15 (Bethyl
Laboratories, Montgomery, TX, USA), rabbit anti-Aurora Kinase A and anti-
p21 (Abcam, Cambridge, UK), goat anti-BIRC3 (RD Systems, Tustin, CA,
USA), mouse anti-Mcl-1 (BD Pharmingen, San Diego, CA, USA) and mouse
anti-beta-actin (Sigma-Aldrich, St Louis, MO, USA).
Immunohistochemistry of engrafted organs embedded in parafﬁn
blocks was performed according to the standard protocols with a speciﬁc
antibody against c-myc.
Microarray analysis
RNA preparation and hybridisation to Affymetrix Human Gene 1.0ST Arrays
was performed in eight primary ALL samples both before and after 6 h
treatment with 1 mM JQ1 according to the manufacturer’s protocol
(Affymetrix, Santa Clara, CA, USA).
Gene expression analysis of the array data was carried out using the
Affymetrix Expression Console with default settings of ‘Default:
RMA-Sketch’. Differentially expressed genes with a P-value o0.001 and
fold change 42 were identiﬁed using limma analysis.22 Gene set
enrichment analysis23 was carried out with the javaGSEA Desktop
Application (http://www.broadinstitute.org/gsea/). To determine genes
predictive of response to JQ1, ranking according to EC50 value and
Spearman’s rank correlation coefﬁcient analysis was performed in
untreated, basal, ALL samples. This identiﬁed a set of genes that was
subsequently subjected to cytoscape analysis (http://www.cytoscape.org/)
to identify cellular pathways inﬂuencing the level of JQ1-induced
cellular death.
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Figure 1. ALL cell lines and primary tumours exhibit sensitivity to JQ1 in vitro. (a) Western blots showing expression of the 80-kDa BRD4
protein in B-precursor ALL cell lines, NALM-6, NALM-17, REH, SD1, SUPB-15 and TOM-1 (left). Ten representative primary B-precursor ALL
samples show Brd4 expression levels that remained mostly unchanged following 6h exposure to 1 mM JQ1 (right). (b) Cell lines NALM-6,
NALM-17, REH, SD1, SUPB-15, TOM-1 and Jurkat were seeded into opaque 96-well plates (5 104 cells per well) and cultured in the presence
or absence of increasing concentrations of JQ1 (0.001–100 mM). Cell lines incubated withX1mM JQ1 for 72 h show a dramatic loss of viability.
Low drug doses can result in a phenomenon called compensatory proliferation as observed here for SUPB-15 and Jurkat.42,43 Data are
presented as mean±s.e.m., and statistical significance was determined by paired, two-tailed Student’s t-test (*Pp0.05, **Pp0.005).
(c) Compared with peripheral blood mononuclear cell obtained from three healthy individuals, representative primary ALL and AML samples
show a differential loss of viability upon 48 h incubation with JQ1. Data are presented as JQ1 concentration required to affect 50% of cells
(EC50) determined using Calcusyn Version 2.1 for Windows software (Biosoft, Paolo Alto, CA, USA).
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Figure 2. ALL tumour cells exhibit sensitivity to JQ1 in vivo. (a) Subcutaneous NALM-6 tumours show significant impairment of growth upon
treatment with 50mg/kg JQ1 (n¼ 8) for 5 days a week over a total of 2 weeks compared with tumours treated with vehicle (n¼ 8). This
difference in tumour size is shown in the photograph of two representative animals, treated with vehicle (10% (w/v) 2-hydroxy-propyl-b-
cyclodextrin, Sigma-Aldrich) or JQ1 respectively (top left-hand inset). Intraperitoneal treatments commenced upon evidence of visible
tumours, and tumours were measured thrice weekly by calliper. (b) In a xenograft of a primary sample, ALL-105 treatment with 50mg/kg JQ1
(n¼ 7) for 5 days a week over 4 weeks leads to a visible reduction in engrafted spleen size/weight (inset and right-hand panel), accompanied
by a significant reduction of splenic engraftment (middle panel) and therefore reduced tumour load compared with vehicle treatment as
assessed by fluorescence-activated cell sorting analysis (n¼ 7). The remainder of cells are of murine origin. Data are presented as mean±s.d.,
and statistical significance was determined by unpaired, two-tailed Student’s t-test (*Pp0.05, **Pp0.005).
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Figure 3. JQ1 targets primary ALL cells with high MYC expression and downregulates multiple pro-survival pathways. (a) SYBR Green
quantitative reverse transcriptase PCR (Q-PCR) was performed using 7500 Fast Real Time PCR system (Applied Biosystems, Warrington, UK),
and comparative Ct method44 was applied to normalise and quantify expression levels. Primer sequences are available on request. Q-PCR
shows differential expression of CDKN1A and MYC in JQ1-resistant (EC50410 mM) versus JQ1-sensitive (EC50o10mM) primary ALLs (total
n¼ 12). Data are expressed relative to JQ1-resistant samples, and the differences in mRNA levels were analysed by a one-tailed t-test
(*Pp0.05). (b) Heat-map, generated using dChip (http://www.dchip.org/) with the default settings, shows a selected subset of genes
downregulated or upregulated in eight primary ALLs by 6 h treatment with 1 mM JQ1. Downregulated genes belong to multiple pro-survival
pathways and include c-Myc targets, the JAK/STAT pathway, and also members of the interleukin gene family. Each column represents a
different patient sample and each row represents a single gene. Colour changes within a row indicate expression levels relative to the average
of the same population. Red indicates upregulation and blue indicates downregulation. (c) Downregulation (IL7R, BIRC3, TNFSR4, MYC) or
upregulation (PPP1R13B, EIF4EBP2) of representative genes induced by 6 h treatment with 1 mM JQ1 is confirmed by Q-PCR in a selection of
primary ALL samples (n¼ 10), some included and some not in the microarray analysis. JQ1 causes a modest reduction in MYC mRNA levels.
The differences in mRNA levels were analysed by a two-tailed t-test.
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Cell cycle and DNA ﬁbre analysis
Cell cycle was analysed by ﬂuorescence-activated cell sorting analysis of
BrdU and propidium iodide-labelled cells.24 Brieﬂy, 3 106 NALM-6 cells
were pulse-labelled with 10mM BrdU, ﬁxed in ethanol, incubated in 15mM
pepsin and 2N HCl before incubation with a mouse anti-BrdU antibody
(Dako, Cambridge, UK) and appropriate secondary antibody (Vector
Laboratories, Peterborough, UK). For total DNA staining, cells were
stained with propidium iodide.
Replication tract abnormalities were detected by the previously
described DNA ﬁbre technique25 to visualise the effect of JQ1 on DNA
replication. Ongoing replication forks in proliferating cells were pulse-
labelled with two different thymidine analogues, 5-chloro-20-deoxyuridine
and 5-iodo-20-deoxyuridine, which are incorporated into newly synthesised
DNA. Subsequent differential immunostaining with speciﬁc antibodies
enabled the visualisation of different replication intermediates such as
replication origins, ongoing replication forks and terminated or stalled
forks, as well as measurement of the speed of ongoing replication forks.
For dual labelling of replication tracts, exponential cell cultures
were pulse-labelled with 25 mM CIdU (Sigma-Aldrich) followed by 250mM
IdU (Sigma-Aldrich), for 20min each. For immunodetection of CIdU- and
IdU-labelled tracts, acid-treated ﬁbre spreads were incubated with a mix of
rat anti-BrdU monoclonal antibody, clone BU1/75 (ICR1) (Serotec, Oxford,
UK) and mouse anti-BrdU monoclonal antibody (Becton Dickinson, Oxford,
UK). Slides were ﬁxed in 4% paraformaldehyde (Sigma) and incubated with
a mix of AlexaFluor 555-conjugated goat anti-rat and AlexaFluor 488-
conjugated goat anti-mouse immunoglobulin G (IgG) (Molecular Probes,
Eugene, OR, USA). Fibres were examined using a Nikon, (Melville, NY, USA)
Eclipse E600 microscope with a  60 lens and images acquired using the
Volocity package (Perkin Elmer, Hopkinton, MA, USA). For replication fork
speeds, the lengths of red- (CIdU-AlexaFluor 555) and green- (IdU-
AlexaFluor 488) labelled patches were measured using the ImageJ
software (http://rsb.info.nih.gov/ij/). Length values were converted into
kb using the conversion factor 1 mm¼ 2.59 kb. Replication structures as
shown in Figure 6a were counted using the Cell Counter plugin for ImageJ.
ALL xenograft models
Animals were treated in accordance with the UK Home Ofﬁce guidelines,
Schedule 1. Subcutaneous tumour cell line xenograft models were
generated following injection of 1 106 cells subcutaneously into the left
ﬂank of NOG mice. Primary ALL xenografts were generated by intravenous
injection of 1 106 tumour peripheral blood mononuclear cells into NOG
mice. Intraperitoneal treatments commenced upon evidence of X1%
human CD45þ leukaemic cells in peripheral blood.
RESULTS
JQ1 has cytotoxic effect in ALL cell lines and primary ALL both
in vitro and in vivo
We ﬁrst observed that the level of expression of BET protein BRD4
was uniform in representative ALL cell lines and primary ALL
samples. Consistent with an effect on BRD4 activity rather than
transcription, JQ1 had no impact on BRD4 expression in primary
ALL cells (Figure 1a). We subsequently determined cell viability
following 72 h exposure to increasing doses of JQ1 in a panel of
ALL cell lines including Phþ ALL (SUPB-15, SD1, TOM-1), Ph ALL
(REH) that exhibit a defective apoptotic response to IR in vitro and
Ph (NALM-6, NALM-17) with a normal apoptotic response to IR,
as well as T-ALL (Jurkat). An impressive decrease in cell viability
was observed in all cell lines tested, with EC50 values o850 nM
(Figure 1b).
In comparison, 26 primary B-precursor ALL samples showed a
range of cytotoxic responses with EC50 values o10 mM for the
majority of tumours (20/26) (Figure 1c). These sensitive cases
exhibited cytogenetic abnormalities commonly observed in
paediatric or infant ALL, such as hyperdiploidy, t(12;21), t(1;19)
and MLL rearrangements (Supplementary Table 1), and repre-
sented a mixture of leukaemias with high or low MRD risk after
induction treatment. No association was observed between any
particular cytogenetic abnormality or MRD risk and JQ1 response.
Notably, four primary leukaemias, one with high-risk MRD (ALL-
123) and three with low risk MRD (ALLs 124, 109 and 102), were
less responsive to JQ1 (EC50 X19 mM). Consistent with previous
reports,16,19,20 primary paediatric AML samples were sensitive to
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Figure 4. JQ1 reduces pro-survival protein expression and induces apoptosis. (a) Western blots showing, in addition to c-Myc, uniform
downregulation of the pro-survival protein Birc5, variable downregulation of Mcl-1 and Birc3 and an unchanging expression of Bcl-2 in the
ALL cell lines NALM-6, SD1 and TOM-1. Cleavage of the proteins PARP1 and caspase-7 over a 96-h incubation period with 1mM JQ1 is
suggestive of induction of apoptosis. Actin shows equal loading. (b) Western blots show no evidence of either p53 upregulation, p53
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the p53 target p21.
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JQ1 (EC50 1.08±0.75), whereas in control peripheral blood
mononuclear cells, cytotoxicity could not be observed for the
same dose range (EC50 4800 mM).
We proceeded to test the impact of JQ1 on ALL proliferation
in vivo. Following formation of subcutaneous tumours of the ALL
cell line NALM-6, animals received either JQ1 or vehicle alone.
We observed a dramatic reduction of tumour growth in
JQ1-treated animals, compared with those given vehicle
treatment (Figure 2a). This was accompanied by prolonged
event-free survival as JQ1-treated tumours never attained
1500mm3 tumour size over the experimental time course
(Supplementary Figure 1A).
Similarly, JQ1 treatment induced both a dramatic reduction of
tumour load in a primary ALL xenograft model created from a
high-risk primary B-precursor ALL (ALL-105) (Figure 2b) and
extended event-free survival (X25% hCD45þ cells in peripheral
blood) by at least 24 days (Supplementary Figure 1B). The
engrafted leukaemia revealed the presence of early CD34þ
CD19þCD10 , intermediate CD34þ CD19þCD10þ and late
CD34CD19þCD10þ ALL progenitors that had the capacity to
proliferate in vivo. We also observed a small percentage of
CD34CD19þCD10 cells in engrafted spleens, whose
malignant origin was uncertain. We noted JQ1-induced reduction
of all the three ALL progenitors, with the greatest effect being
exerted on the CD34þ CD19þCD10þ subset (Supplementary
Figure 1C).
We conclude that JQ1 exhibits a cytotoxic effect on ALL cells
both in vitro and in vivo and that this effect is independent of the
ALL phenotype.
JQ1 targets primary ALL cells with high MYC levels and
downregulates multiple pro-survival pathways
Given that clinical and cytogenetic proﬁles of primary ALL samples
did not inﬂuence the response to JQ1, we addressed whether their
global gene expression proﬁles could provide additional informa-
tion. Spearman’s rank correlation was implemented on global
transcription proﬁles of eight untreated, representative ALL cases
with a range of cytotoxic responses to JQ1, and identiﬁed a set of
398 genes whose basal expression correlated with JQ1 EC50
values (Supplementary Table 2). Subsequent cytoscape analysis to
identify common cellular functions highlighted two major path-
ways predictive of cytotoxic response to JQ1; one associated with
ATM and related double-strand break repair genes, and the other
linked with the cell cycle inhibitor CDKN1A (Supplementary
Figure 2). We focused on the cell cycle inhibitor CDKN1A mRNA,
and in a quantitative PCR validation experiment, we demonstrated
that CDKN1A expression was signiﬁcantly lower in ALL samples
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Figure 5. JQ1 downregulates MYC at both the transcriptional and the post-transcriptional level and induces cell cycle arrest. (a) Quantitative
PCR showing a transient decrease of MYC mRNA in the cell line, NALM-6, following 6 h after treatment with 1 mM JQ1. Statistical significance
was determined by a paired, two-tailed Student’s t-test (*Pp0.05, **Pp0.005). (b) Western blots showing that proteasome inhibition with
10mM proteasome inhibitor MG132 (Merck, Whitehouse, Station, NJ, USA) prevents downregulation of c-Myc after 24 h of incubation with 1 mM
JQ1 in the ALL cell lines NALM-6 and TOM-1 (top). Inhibition of translation by 100 mM anisomycin (Sigma) over a 6-h time course in NALM-6
cells leads to accelerated decrease in c-Myc expression in the presence of JQ1 (c-Myc half-life is 2 h in JQ1-treated cells and46h in untreated
cells) (middle). Aurora A kinase expression is depleted in NALM-6 and TOM-1 cell lines after 24 h of JQ1 treatment (bottom). (c) All four ALL cell
lines (TOM-1, SUPB-15, SD1 and NALM-6) show an induction of G1 arrest following 24 h exposure to 1 mM JQ1 upon staining with 25 mg/ml
propidium iodide (Sigma).
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with low JQ1 EC50 values, whereas it’s upstream negative
regulator MYC was signiﬁcantly higher in the same category of
leukaemias (Figure 3a). We conclude that high MYC and low
CDKN1A levels, likely to reﬂect an imprint of prior high
proliferation in patients, render primary ALLs sensitive to BET
inhibition.
To fully understand the JQ1-induced cytotoxic activity in
primary paediatric ALL and identify the additional pathways
that might be affected by BET inhibition, we next analysed
JQ1-induced changes in global gene expression in the same eight
primary ALL samples. Comparison of proﬁles before and after 6 h
exposure to 1 mM JQ1 identiﬁed a total of 96 differentially
downregulated genes in JQ1-treated cells. Consistent with a
recently published report on ALL cell lines,21 we also observed
downregulation of the IL-7 receptor gene (IL7R) that mediates
pro-survival signalling via the JAK/STAT pathway (Figures 3b and c).
Additional downregulated genes included those involved in the
inhibition of apoptosis, such as the NFkB target gene BIRC3, the
FAIM3 gene encoding the anti-apoptotic factor Toso, SENP1-,
ALKBH8- and CARD6-encoding proteins associated with the
promotion of cancer cell survival, and also the MYC gene, a key
regulator of cell proliferation, which exhibited higher basal levels
in the more JQ1-responsive leukaemias. Subsequent assessment
of downregulated genes by gene set enrichment analysis revealed
multiple pro-survival pathways, including members of the
JAK-STAT, NFkB, c-Myc and cytokine (IL-2, IL-7, IL-10, IL-17), and
G-protein-coupled receptor pathways (Supplementary Table 3).
A total of 127 genes were upregulated upon JQ1 treatment and
included those with a role in translational repression (EIF4EBP2,
PAIP2B), induction of apoptosis (PPP1R13B) and tumour suppression
(glucocorticosteroid (GC)-responsive gene FKBP51) (Figure 3b).
We performed validation of genes relevant for ALL survival and
proliferation, the pathways identiﬁed as being deregulated by JQ1,
in a cohort that included ALL samples previously interrogated by
microarray analysis, but also in those that were not analysed
but were representative of the heterogenous nature of this
malignancy. We conﬁrmed a moderate decrease in MYC expres-
sion and a signiﬁcant reduction (IL7R, BIRC3, TNFSR4) or elevation
(PPP1R13B and EIF4EBP2) in the expression of these selected genes
at the cytotoxic dose of JQ1 (Figure 3c).
Interestingly, when we addressed JQ1 effects at the protein
level in ALL cell lines with a diversity of genetic backgrounds,
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Figure 6. JQ1 inhibits DNA replication in ALL cells. (a) A schematic of DNA fibre labelling and representative images of replication forks in
dimethyl sulphoxide- or JQ1-treated cells are given on the left, and a schematic representation of replication structures is given on the right.
(b) The reduced lengths of IdU-labelled tracks reveal increased replication fork stalling in NALM-6 cells in the presence of 1 mM JQ1 over 24 h.
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reduction in the number of cycling cells in NALM-6 cells treated with increasing concentrations of JQ1. (e) Treatment of NALM-6 cells with JQ1
over 1 h also reduces progression of replication forks. Statistical significance was determined by a two-tailed Mann–Whitney test (**Pp0.005).
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we observed the most profound effect on both the cell
cycle regulator c-Myc and the pro-survival protein
BIRC5/survivin, which were completely abrogated in all cell
lines tested by 48 h (Figure 4a). The effect on BIRC3 and Mcl-1
was variable between cell lines, whereas Bcl-2 levels remained
unchanged.
Consistent with the ability of JQ1 to downregulate multiple
pro-survival proteins, JQ1-treated cells exhibited evidence of
p53-independent apoptosis. By 72 h of treatment, modest
apoptosis could be detected by cleavage of PARP1, procaspase -7,
-3 and by annexin V staining (Figure 4a, Supplementary Figure 3).
In contrast to treatment with the DNA-damaging agent
daunorubicin, JQ1-treated NALM-6 cells showed no evidence
of p53 upregulation, p53 phosphorylation or p21 upregulation
by western blot (Figure 4b).
JQ1 decreases c-Myc stability
In agreement with published data, we found that although MYC
mRNA levels were only moderately affected (Figures 3c and 5a),
c-Myc protein was completely depleted by 24 h of JQ1 treatment
in ALL cell lines (Figure 4a). Thus, we addressed the possibility that
BET proteins might be involved in regulation of c-Myc stability.
Consistent with this notion, BRD4 has been previously implicated
in the regulation of the stability of papillomavirus-encoded E2
protein.26 We subsequently exposed NALM-6 and TOM-1 cells to
1 mM JQ1 for 24 h in the presence or absence of the proteasome
inhibitor MG132 (Figure 5b) and observed that MG132 completely
abolished JQ1-induced loss of c-Myc expression. Furthermore,
inhibition of protein translation by anisomycin in NALM-6 cells led
to an accelerated decrease in c-Myc expression in the presence of
JQ1 (Figure 5b).
As c-Myc stability is regulated by Aurora A kinase,27
we addressed the possibility that JQ1-induced Aurora A
downregulation might be associated with the loss of c-Myc
expression. A concordant loss of c-Myc and Aurora A expression
was detected in ALL cell lines by 24 h of treatment with JQ1
(Figure 5b). This suggests that JQ1 can indirectly modify c-Myc
stability and stresses a potential role for BET proteins in the
regulation of cellular proteins, not only at the transcriptional but
also at the post-transcriptional level. As expected, JQ1-induced
c-Myc downregulation was associated with G1 arrest in all ALL cell
lines (Figure 5c).
JQ1 inhibits DNA replication
As BET inhibition was able to reduce but not completely abolish
cell cycle progression, we next investigated the effect of JQ1 on
cells in S phase. Both c-Myc and BRD4 have been reported to have
a role in DNA replication28,29 and we reasoned that BET inhibition
might compromise this highly regulated process, either directly or
via its effect on c-Myc expression.
We showed that 24 h exposure of NALM-6 cells to 1 mM JQ1 led
to increased replication fork stalling as indicated by shortening
speciﬁcally of the second label in ongoing forks (Figures 6a and b)
and a substantial increase in the percentage of stalled replication
fork structures (Figure 6c). To exclude the possibility that the
observed effects on replication were caused by an accumulation
of cells in a speciﬁc stage of the S phase, we measured BrdU
incorporation in the same cell line (Figure 6d). We noted that
JQ1-treated cultures exhibited a low proportion of S-phase cells,
but those cells that had entered the S phase underwent DNA
replication without accumulation in any particular S-phase stage.
Furthermore, a short 1 h exposure of NALM-6 cells to 1 mM JQ1,
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insufﬁcient to cause c-Myc downregulation, also led to a marked
reduction in fork progression rates (Figure 6e). We conclude that
reduced replication fork progression rates and increased replica-
tion fork stalling are caused by a direct effect of JQ1 on replication,
rather than perturbation of the S phase itself, or by an indirect
effect of c-Myc depletion.
JQ1 sensitises ALL cells to dexamethasone, both in vitro and in vivo
The observed cellular consequences of JQ1 activity, namely the
induction of G1 arrest, downregulation of pro-survival signalling
and modulation of DNA replication provided a rationale for
combined treatment.
GCs are a principal component of current therapeutic protocols
for paediatric ALL, and sensitivity to GCs is still the most important
prognostic parameter in this type of leukaemia.30 It has been
recently shown that dexamethasone induces cellular death by
autophagy;31 however, the mechanisms underlying response to
corticosteroids are complex and not fully understood.30,32–34
Given that JQ1 downregulates multiple pro-survival genes that
differ from GS targets35 (Supplementary Figure 4), we hypothe-
sised that low doses of JQ1 would sensitise ALL cells to killing by
dexamethasone. Indeed, signiﬁcant sensitisation was observed
in vitro, in two dexamethasone-resistant cell lines, NALM-17 and
REH (Figure 7a). However, the synergistic relationship could be
calculated for the two cell lines (NALM-6 and TOM-1) that were
sensitive to both reagents. This revealed that JQ1 and dexa-
methasone also acted synergistically at a minimal level even in cell
lines that responded well to both drugs individually, thus possibly
allowing them to be used at doses that could reduce side effects
of these individual therapies (Supplementary Table 4). Similarly,
two primary ALLs (ALL-130 and ALL-132) could be sensitised to
dexamethasone in vitro by addition of JQ1, whereas the effect in
the highly JQ1-sensitive primary tumour (ALL-129) was less
evident (Figure 7b, Supplementary Table 5).
Finally, to address whether this in vitro sensitisation could be
recapitulated in vivo, we treated a xenograft model of primary
ALL-132 with a reduced dose of JQ1, with or without dexametha-
sone. Although this lower dose of JQ1 was insufﬁcient to suppress
leukaemic proliferation (Figure 8a), it led to downregulation of
c-Myc (Figure 8b). In contrast, we observed a signiﬁcant reduction
in tumour load in animals co-treated with JQ1 and dexametha-
sone. Equally, in a xenograft model of the dexamethasone-
resistant ALL cell line REH, we observed signiﬁcantly reduced
subcutaneous tumour growth under combined JQ1/dexametha-
sone treatment (Figure 8c). In addition, co-treatment conferred a
survival advantage in both models (Supplementary Figure 5).
DISCUSSION
In this study, we presented a novel approach to the treatment of
ALL that targets the histone acetyl-lysine-binding bromodomains
of BET proteins, which regulate epigenetic memory and transcrip-
tional activity. We showed that inhibition of BET proteins led to
downregulation of multiple pro-survival genes, as well as cell cycle
arrest and replication fork stalling. This caused cytotoxic effects in
ALL cell lines as well as primary ALL cells irrespective of their
phenotype, both in vitro and in vivo ALL xenograft models.
It has been reported that inhibition of the c-Myc-induced
transcriptional program represents one of the principal mechan-
isms of cellular killing caused by BET inhibition.17–20 Consequently,
the BET inhibitor JQ1 suppresses c-Myc-driven malignancies, such
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Figure 8. JQ1 in combination with dexamethasone reduces proliferation of ALL tumour cells in vivo. (a) In the primary xenograft model with
ALL-132, intraperitoneal co-treatment (n¼ 5) with JQ1 (25mg/kg five times per week) and dexamethasone (10mg/kg three times per week)
for 3 weeks led to a significant reduction of engrafted cells both in infiltrated murine spleens and bone marrow compared with either
dexamethasone or JQ1 treatment alone (n¼ 4) (left-hand panel). The concomitant decrease in splenic size upon co-treatment indicates
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with JQ1 alone (n¼ 5) had no significant effect on tumour load compared with vehicle treatment (n¼ 4). (b) Immunohistochemistry images
reveal that JQ1 treatment of primary ALL xenografts resulted in downregulation of c-Myc in engrafted spleens and bone marrow.
c-Myc-positive cells are stained brown as indicated by the arrows. (c) Subcutaneous REH tumours show significant reduction in growth when
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as nuclear protein in testis-midline carcinoma, AML and multiple
myeloma, by displacement of BRD4 from the MYC promoter/
enhancer.17,18 In this study, we have shown that BET inhibition
downregulates not only MYC transcription but also reduces
stability of c-Myc protein.
We addressed transcriptional markers of sensitivity to BET
inhibition in primary ALL samples and observed that the cytotoxic
response correlated with the expression of MYC and its target
CDKN1A and that cases with the highest level of MYC expression
exhibited low EC50 values. This is not surprising given the
fundamental role of c-Myc downregulation in JQ1-induced
cytotoxicity and suggests that highly proliferative and more
aggressive ALL cases are more likely to be amenable to this new
therapeutic strategy. Furthermore, as induction of apoptosis by
JQ1 was not associated with p53 activation, there is a possibility
that a wide range of apoptotic-resistant leukaemias, including
those with p53 dysfunction, could be sensitive to BET inhibition.
Most importantly, proliferation of ALL progenitors at different stages
of differentiation were affected in JQ1-treated ALL xenografts.
Of note, we observed a differential sensitivity of ALL cells
compared with non-leukaemia peripheral blood mononuclear
cells. This was in agreement with a previous study, where short
hairpin RNA suppression of BRD4 failed to inﬂuence the growth of
non-transformed G1E erythroblast cells, despite a clear cytotoxic
effect on AML cells.16
The question of whether the JQ1-induced cytotoxic effect can
be entirely attributed to c-Myc downregulation remains intriguing.
Several lines of evidence suggest that this might not be the case.
For example, it has been previously observed that ectopic MYC
expression was unable to prevent JQ1-induced cell death16 and
that resistance to JQ1 can occur despite c-Myc downregulation.19
Our results support the notion that BET inhibition exerts an anti-
tumour effect by a variety of mechanisms and that the cytotoxic
effect of BET inhibition expands beyond c-Myc downregulation.
First, we showed that in primary ALL cells, JQ1 led to substantial
downregulation of different pro-survival pathways, including JAK/
STAT and interleukin signalling components, that seem to be
unaffected by BET inhibition in other malignancies studied so far.
Second, our DNA ﬁbre analysis suggests that JQ1-treated ALL cells
in S phase exhibit not only reduced replication fork progression
rates but also an increased frequency of stalled replication forks.
This is consistent with a direct role for JQ1 in the induction of
replicative stress. Although BrdU incorporation showed that
JQ1-treated cells do not accumulate in S phase, this does not
exclude the possibility that JQ1-treated cells might progress
through S phase more slowly. At this stage, it is difﬁcult to
envisage the exact mechanism behind this defective replication;
however, it is conceivable that upon BET inhibition, initiated but
incompleted transcription complexes pose a physical obstacle for
the replication process.24
BET inhibition sensitised both primary ALL and ALL cell lines to
dexamethasone. GC sensitivity remains an important predictor of
clinical outcome, and many European paediatric ALL trials include
pre-treatment with GCs as an important stratifying step.36–39 The
survival advantage associated with dexamethasone over
prednisolone in the treatment of ALL has been demonstrated in
randomised controlled trials, although concerns remain regarding
the relative toxicity.40 Thus, mechanisms to enhance the
therapeutic efﬁcacy of glucocorticoids would be of clinical
interest.41 We observed JQ1-induced sensitisation to
dexamethasone, both in vitro and in vivo, in two ALL xenograft
models. The possibility that JQ1 and GCs target different pro-
survival pathways in ALL cells could account for the observed
sensitisation and would support this combination as a useful
therapeutic approach for a wide range of ALL cases.
In conclusion, our results suggest that BET inhibition is an
important novel target for paediatric ALL, irrespective of conven-
tional prognostic features. We demonstrate that BET inhibition
causes inhibition of the cell cycle and replication, repression of
transcription and induction of apoptosis. Importantly, this effect
could be enhanced by combining JQ1 with dexamethasone. Our
data strongly supports the rationale for targeting BET proteins as a
new therapeutic strategy that can enhance the efﬁcacy of current
therapies.
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